The Lung Cancer Research Foundation (LCRF) announces the first recipients of its LCRF Team Science Award on Advancing Therapies Toward Curing EGFR Mutated Lung Cancers. The project, "A novel ...

The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.

Scientists have discovered that increased expression of a novel long non-coding RNA drives glioblastoma cell growth alongside ...

Nephrologists now have an approved treatment option for FSGS patients without nephrotic syndrome following the latest FDA ...

BDTX bets on silevertinib's broad EGFR mutation reach and CNS activity, but with no approved products, upcoming 2026 data and partnerships are pivotal.

Aumolertinib and osimertinib showed similar efficacy and safety in treating EGFR-mutant NSCLC, with no significant differences in progression-free survival or overall survival. The study involved 202 ...

As eGFR decreased, risks for 30-day hospital readmission or death increased for patients with chronic kidney disease, according to study data published in Clinical Journal of the American Society of ...

Stopping RAS inhibitors after eGFR decline may raise risk of kidney failure and death. Learn more about this new study.

For years, Nichole Jefferson battled a series of health problems as she juggled a stressful job in the tech industry while raising her daughter. Then, in 2003, she wasn’t feeling well and went to a ...